Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company targeting the domestic pharmaceutical manufacturing sector. The "II" designation marks it as a sequel vehicle from the same sponsor team behind the original Drugs Made In America Acquisition Corp., reflecting continued sponsor interest in reshoring U.S. drug production amid ongoing supply-chain policy debates. The company filed an 8-K with the SEC on March 17, 2026, under accession number 0001213900-26-029050, signaling a material corporate update in its search for a combination target. DMII operates within the healthcare and life sciences SPAC space, a segment that has drawn sustained attention from deal-focused investors. Visit SpacDesk and sign up for full data on DMII, including filing history, timeline milestones, and sponsor background.